The Janus Kinase 2 (JAK2) plays essential roles in transmitting signals from multiple cytokine receptors, and constitutive activation of JAK2 results in hematopoietic disorders and oncogenesis. JAK2 kinase activity is negatively regulated by its pseudokinase domain (JH2), where the gain-of-function mutation V617F that causes myeloproliferative neoplasms resides. In the absence of a crystal structure of full-length JAK2, how JH2 inhibits the kinase domain (JH1), and how V617F hyperactivates JAK2 remain elusive. We modeled the JAK2 JH1–JH2 complex structure using a novel informatics-guided protein-protein docking strategy. A detailed JAK2 JH2-mediated auto-inhibition mechanism is proposed, where JH2 traps the activation loop of JH1 in an inac...
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Th...
JAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases (PTKs), is an important ...
Hyperactive mutation V617F in the JAK2 regulatory pseudokinase domain (JH2) is prevalent in patients...
Janus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is required for biolog...
BACKGROUND: The tyrosine kinase Janus kinase 2 (JAK2) is important in triggering nuclear translocati...
Janus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is required for biolog...
Homeostasis of the human body depends on the immune system regulated via specific signaling pathways...
textabstractJanus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is require...
Gain-of-function mutations in the genes encoding Janus kinases have been discovered in various haema...
The Janus kinase-signal transducer and activator of transcription protein (JAK-STAT) pathway mediate...
Janus kinase 2 (JAK2) is a protein tyrosine kinase central to amultitude of cellular processes. Here...
The mechanisms by which JAK2 is activated by the prevalent pseudokinase (JH2) V617F mutation in bloo...
Pseudokinases lack conserved motifs typically required for kinase activity. Nearly half of pseudokin...
Background: Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in the...
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Th...
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Th...
JAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases (PTKs), is an important ...
Hyperactive mutation V617F in the JAK2 regulatory pseudokinase domain (JH2) is prevalent in patients...
Janus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is required for biolog...
BACKGROUND: The tyrosine kinase Janus kinase 2 (JAK2) is important in triggering nuclear translocati...
Janus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is required for biolog...
Homeostasis of the human body depends on the immune system regulated via specific signaling pathways...
textabstractJanus kinase 2 (JAK2) initiates signaling from several cytokine receptors and is require...
Gain-of-function mutations in the genes encoding Janus kinases have been discovered in various haema...
The Janus kinase-signal transducer and activator of transcription protein (JAK-STAT) pathway mediate...
Janus kinase 2 (JAK2) is a protein tyrosine kinase central to amultitude of cellular processes. Here...
The mechanisms by which JAK2 is activated by the prevalent pseudokinase (JH2) V617F mutation in bloo...
Pseudokinases lack conserved motifs typically required for kinase activity. Nearly half of pseudokin...
Background: Janus kinases (JAKs; JAK1 to JAK3 and tyrosine kinase 2) mediate cytokine signals in the...
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Th...
The JAK2 V617F mutation present in over 95% of Polycythemia Vera patients and in 50% of Essential Th...
JAK2, a member of the Janus kinase (JAK) family of protein tyrosine kinases (PTKs), is an important ...
Hyperactive mutation V617F in the JAK2 regulatory pseudokinase domain (JH2) is prevalent in patients...